ROADMAP project holds 2nd General Assembly in Barcelona 24 Mar 2017

On 23 and 24 March, the partners of the ROADMAP project met for the 2nd General Assembly Meeting of the project in Barcelona, Spain. The meeting was chaired by John Gallacher (University of Oxford) and Frederic de Reydet de Vulpillieres (Novartis on behalf of EFPIA). The aim of the meeting was to provide an overview of the progress of the project and to identify opportunities for further cross-Work Package collaboration.

Altogether, ten main topics were presented and discussed. During the first day, these included the recently accepted “D2.1 First list of priority real-world evidence relevant outcomes for AD” and progress on the literature review on disease models and Industry/Health Technology Assessment (HTA) economic models, as well as hands-on data extraction pilots from different countries.

During the second day, the current selection of disease models and their validation were discussed. This presentation was followed by a fingerprints demo on data source overview and characterisation. Jacoline Bouvy (NICE), Christine Gispen (College ter Beoordeling van Geneesmiddelen) and Robin Thomson (Biogen) introduced the work on regulatory and HTA engagement, including the platform to engage with regulators/HTA bodies.

Following on from that, the Ethical, Legal and Social Implications (ELSI) literature review possibilities were discussed with regard to potential scenarios. The presentations ended with an overview of the communications plan and tools, including the launch of the website. The meeting was closed by the members of the Executive Committee with a recapitulation of action items and an outlook on the next meetings.

The official ROADMAP website which was launched during the General Assembly, includes recent news, access to the official ROADMAP twitter handle and an overview of the project’s Work Packages as well as the projects partners. Visitors also have the opportunity to subscribe to the project’s quarterly newsletter.

Receive the latest news. Click here to subscribe!

More News